Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC: New York Monday, September 16, 2024, 10:00 Hrs [IST ...

This summary covers various health news: a Nipah virus death in Kerala, Gaza's polio vaccination coverage success, brain ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

A summary of current health news, including a Nipah virus death in Kerala, an mpox case rise in Uganda, and Pfizer's efforts ...

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

With rate cuts on the way, growth and income investors should grab quality dividend stocks with high yields like these and hold them forever.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.